For Immediate Release
January 12, 2023
BETHESDA, Md. – The Association for the Advancement of Blood & Biotherapies (AABB) is proud to introduce the AABB Biotherapies Corporate Membership Program, an initiative designed to ease challenges that biotherapies companies face, including workforce development, quality systems control and regulatory support.
AABB’s new Biotherapies Corporate Membership was developed to be an essential resource for biotech companies looking to accelerate their speed to market. Key benefits of the membership include:
“From the very beginning of their membership, biotherapies companies will be provided with private onboarding and customized training with highly experienced consultants. The membership package includes a retainer package with AABB’s world-renowned consulting service team, which will not only help each corporate member connect with off-the-shelf benefits, but will also allow for customized services to meet each company’s needs.” said Debra BenAvram, CEO of AABB.
This unique membership type offers a pivotal opportunity for biotherapies companies to deliver high-quality solutions for patients – faster and at lower costs. Developed to cater to the need of biotherapy companies in start-up mode, at the commercial stage or in between, AABB’s new Biotherapies Corporate Membership aims to help fill the need for solutions that ease the pressures of rapid growth, high demand, regulatory adherence and consumer understanding. An AABB Biotherapies Corporate Membership, will help companies achieve high-value results and expanded networks through:
AABB (Association for the Advancement of Blood & Biotherapies) is an international, not-for-profit organization representing individuals and institutions involved in the fields of transfusion medicine and biotherapies. The Association works collaboratively to advance the field through the development and delivery of standards, accreditation and education programs. AABB is dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide.